Connect with us

Press Releases

Restalyst de Singapur desarrolla un test de anticuerpos de COVID-19 altamente sensible comparable a los líderes del mercado

SINGAPUR, 24 de agosto de 2020 /PRNewswire/ — Restalyst, una compañía biomédica de Singapur, ha desarrollado el COVID19N-REAAD™, un test de anticuerpos de COVID19, que será fundamental para establecer la prevalencia de la enfermedad en las poblaciones y los factores de riesgo de…

Avatar

Published

on

SINGAPUR, 24 de agosto de 2020 /PRNewswire/ — Restalyst, una compañía biomédica de Singapur, ha desarrollado el COVID19N-REAAD™, un test de anticuerpos de COVID19, que será fundamental para establecer la prevalencia de la enfermedad en las poblaciones y los factores de riesgo de exposición asociados con el contagio. Esto permitirá a las autoridades sanitarias determinar la efectividad de las medidas de control de COVID-19 y optimizarlas a futuro. La información de los segmentos de población más susceptibles al contagio también ayudará en futuros desarrollos de vacunas.

La necesidad de tests serológicos se ha incrementado, en especial, en la detección de infecciones anteriores en pacientes asintomáticos. Los contagios de COVID-19 se diagnostican a través de la reacción en cadena de la polimerasa con retrotranscripción (reverse transcription polymerase chain reaction, RT-PCR), en tiempo real, que se realiza con un hisopado nasofaríngeo. Confirma la presencia del virus. El RT-PCR no se puede utilizar para evaluar la prevalencia de la enfermedad, dado que un resultado negativo no puede diferenciar a una persona que ha estado contagiada previamente y se ha recuperado de una persona contagiada. A diferencia del RT-PCR, el COVID19N-REAAD™ se concentra en una respuesta inmunitaria de adaptación al COVID-19, que indica un contagio reciente o previo. Funciona empleando un ensayo inmunoabsorbente ligado a enzimas que captura y detecta los anticuerpos específicos de la proteína nucleocápside del COVID-19.

“Los test serológicos como el COVID19N-REAAD™ ayudan en la investigación de la actual epidemia, y en la evaluación retrospectiva de las tasas de contagio y la extensión del brote epidémico. Son valiosísimos para determinar el alcance total de la enfermedad y son vitales para posibilitar una respuesta coordinada y eficaz a nivel nacional ante el brote”, dijo Zaccheus Peh, CEO de Restalyst.

Un estudio que utiliza 387 muestras clínicas –conformadas por 56 RT-PCR positivos y cohorte de 331 sanos para el COVID-19– determinó que COVID19N-REAAD™ tiene una sensibilidad clínica y una especificidad estimadas de 98,21% y 100% respectivamente. El test fue validado a través de estudios comparativos con ADVIA Centaur® SARS-CoV-2 Total de Siemens y Elecsys Anti-SARS-CoV-2 de Roche, tests serológicos aprobados por la FDA. Los estudios se realizaron utilizando 132 muestras serológicas reactivas y 267 muestras serológicas no reactivas según lo determinado por los dos ensayos. Se determinó que COVID19N-REAAD™ tuvo concordancia porcentual positiva, concordancia porcentual negativa y una tasa general de concordancia del 97,73%, 91,01% y 93,23%, respectivamente.

COVID19N-REAAD™ ha recibido la marca CE y la autorización provisoria de la Autoridad de Ciencias de la Salud de Singapur.

Los medios pueden dirigir sus consultas a:

Matthew Mak
Restalyst Pte Ltd
[email protected]
+65 6543 3640

FUENTE Restalyst

SOURCE Restalyst

Source: https://www.prnewswire.com:443/news-releases/restalyst-de-singapur-desarrolla-un-test-de-anticuerpos-de-covid-19-altamente-sensible-comparable-a-los-lideres-del-mercado-885235323.html

Continue Reading

Press Releases

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

MELBOURNE, Australia, Oct. 25, 2020 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Cogstate, Ltd. (Headquarters: Melbourne, Australia and New Haven, USA, CEO: Brad O’Connor, “Cogstate”) announced today that the companies have entered into a…

Avatar

Published

on

Developed by Cogstate, the CBB is a scientifically validated digital tool that enables cognitive function self-checks and consists of four tests evaluating psychomotor function, attention, learning and memory, and working memory. In the United States, Europe, Australia, New Zealand and Canada, the CBB has been adapted as a medical device named “CognigramTM” that has achieved marketing authorization by regulators in these jurisdictions and provides informative results for healthcare professionals to support clinical examination to aid in the diagnosis of MCI and dementia.

In its medium-term business plan, EWAY2025, Eisai is aiming to become a “Medico Societal Innovator” (a company that changes society through creating medicines and providing solutions). Eisai is creating next-generation medical remedies focused on the neurology and oncology areas as well as building disease ecosystem platforms, in order to provide environments and solutions including digital solutions for early diagnosis and early treatment.

Cogstate aims to make assessment of brain health as simple, common and informative as assessment of blood pressure. Cogstate’s technology, which is easy to use and available in over 70 languages, is supported by extensive scientific validation, including more than 600 peer reviewed publications. Cogstate technology has been used extensively in clinical trials, including trials conducted by Eisai.

The global agreement between Eisai and Cogstate will allow the two companies to replicate many of the advancements that have already been launched in Japan, where Eisai has developed and launched a new digital tool using the CBB, named “NouKNOWTM” (pronounced “NOH-NOH”), a non-medical device for self-assessment of brain performance (brain health). Eisai is currently investigating the possibility of developing a medical device using the CBB in Japan.

In recent years, various research has demonstrated the possibility that decline in brain performance may be mitigated through major readjustments to lifestyle, such as regular exercise and sleep, a well-balanced diet, and social interaction. However, according to a survey by Eisai, the number of people taking correct preventive actions or habitually performing self-checks of cognitive function are few, with disparities (“chasms”) existing against the incorporation of these habits into daily lifestyle.

As a result of these findings, in Japan, Eisai is constructing a dementia platform, called “Easiit”, with the goal of erasing these chasms. Core to this platform will be the brain-performance self-check tool “NouKNOW” and the “Easiit App” which aims to contribute to the promotion of health practices through data visualization of brain and body health insights.

It can be expected that the use of “NouKNOW” to perform periodic self-assessments of brain performance among the generation currently in their prime working years, along with the use of the “Easiit App” for the adjustment of lifestyle and practice of preventive measures in daily life, will become an opportunity for the creation of better brain and body health.

Through this agreement, Eisai and Cogstate will work together for the development of digital tools for simpler self-checks of cognitive function and diagnostic tool development for healthcare professionals to promote greater awareness of brain performance globally, thus contributing to the realization of well-being for all.

[Notes to editors]

1. About Eisai Co., Ltd.

Eisai Co., Ltd. defines our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For further information on Eisai Co., Ltd., please visit https://www.eisai.com

2. About Cogstate Ltd.

Cogstate Ltd. (ASX:CGS) is a neuroscience technology company headquartered in Melbourne, Victoria, Australia and New Haven, Connecticut, USA, focused on optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Since 1999, Cogstate technologies have provided rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains. The company’s clinical trials solutions include quality assurance services for clinical outcome assessments that combine electronic data capture, innovative operational approaches, advanced analytics and scientific consulting. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. Notwithstanding this agreement, Cogstate will continue to independently offer its technology and services to the clinical trials market.

For further information on Cogstate, please visit www.cogstate.com.

SOURCE Cogstate Ltd

Source: https://www.prnewswire.com:443/news-releases/eisai-and-cogstate-expand-agreement-for-global-development-and-commercialization-of-digital-cognitive-assessment-technologies-301159248.html

Continue Reading

Press Releases

BIG NEWS: Endangered White Rhino Born at Disney’s Animal Kingdom Theme Park

LAKE BUENA VISTA, Fla., Oct. 25, 2020 /PRNewswire/ — Disney’s Animal Kingdom Theme Park just welcomed a baby white rhinoceros to the family, boosting efforts to save the magnificent and endangered species. After a 16-month pregnancy, the male calf weighing approximately 150 pounds was…

Avatar

Published

on

Calf and mother are doing well under the keepers’ watchful eyes. While rhinos are gregarious by nature; for now, the calf is resting, nursing and bonding with his mom.

The yet-to-be-named rhino is expected to join the “crash” – the term for a group of rhinos – on the theme park’s savanna in the coming weeks. Guests aboard the park’s Kilimanjaro Safaris attraction will then have a chance to see the calf in its habitat.

Kendi was paired with dad Dugan through one of the Species Survival Plans overseen by the Association of Zoos and Aquariums to ensure the responsible breeding of endangered species.

The animal care team is also caring for two other rhinos expected to give birth in 2021. This is especially significant, as white rhinos – the world’s second largest land animal – are an endangered species with a near-threatened status.

For more information on Disney’s Animal Kingdom and Walt Disney World Resort, visit WDWNews.com.

SOURCE Walt Disney World Resort

Source: https://www.prnewswire.com:443/news-releases/big-news-endangered-white-rhino-born-at-disneys-animal-kingdom-theme-park-301159230.html

Continue Reading

Press Releases

MÉXICOPUEDE.MX, en alianza con Cisco México, brinda asesoría a PYMES

CIUDAD DE MÉXICO, 25 de octubre de 2020 /PRNewswire/ — Hemos experimentado grandes retos durante este año, tanto profesionales como personales de cara a una “nueva normalidad” que pone de manifiesto la capacidad que tenemos de adaptarnos y de salir adelante frente a los retos….

Avatar

Published

on

En alianza con Cisco México, a través del equipo de Cisco Designed for Business, y de la mano del experto Saúl Olivera, líder de ventas Regionales y Desarrollo de Negocios de Cisco para el segmento de Small y Medium Business para México, Centro América, Caribe y Norte de Sudamérica, ofrece 3 webinars que brindan una guía clara acerca de la digitalización de las empresas y negocios y de cómo pueden aprovechar las Tecnologías de la Información y Comunicación para mejorar la toma de decisiones, optimizar sus operaciones y ofrecer mejores experiencias a cada uno de sus usuarios y/o consumidores:

  • 28 de octubre a las 18:00 horas
  • 11 de noviembre a las 18:00 horas
  • 25 de noviembre a las 18:00 horas

La reactivación económica es una realidad y, hoy más que nunca, la digitalización marca la diferencia entre el fracaso y el éxito de las micro, pequeñas y medianas empresas. Las compras online han aumentado considerablemente durante la pandemia por COVID-19, por lo que saber aprovechar los beneficios que la tecnología ofrece es una necesidad para todos los negocios.

Esta experiencia única marcará un antes y un después en tu empresa, te invitamos a registrarte en www.mexicopuede.mx y participar. Los eventos son online y gratuitos.

“Estamos muy emocionados por la alianza con MÉXICOPUEDE.MX ya que queremos tener cercanía con sus asociados acompañándolos en su proceso de transformación digital”, comentó Saúl Olivera.

“Es para nosotros muy satisfactorio contar con aliados como Cisco, ya que nos permite ofrecer a los asistentes a los webinars contenidos de la mejor calidad  en beneficio de las micro, pequeñas y medianas empresas”, afirmó Genaro Hurtado, líder iniciador de MÉXICOPUEDE.MX y Fundador de Brivé.

Contacto de prensa en México

María Yáñez, PR Consultant
+5252948215 Ext. 139
[email protected]

www.lizetteweber.com

Foto – https://mma.prnewswire.com/media/1319500/GENARO_HURTADO_2020.jpg 
Foto – https://mma.prnewswire.com/media/1319501/SAUL_OLIVERA.jpg

FUENTE MÉXICOPUEDE.MX

Related Links

https://mexicopuede.mx

SOURCE MÉXICOPUEDE.MX

Source: https://www.prnewswire.com:443/news-releases/mexicopuede-mx-en-alianza-con-cisco-mexico-brinda-asesoria-a-pymes-814464816.html

Continue Reading
Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Press Releases4 hours ago

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

Private Equity4 hours ago

Gulf Capital backs CWB as part of $60mln IP platform build

Private Equity4 hours ago

Allianz-managed AfricaGrow backs first two funds

Private Equity4 hours ago

Lilium Capital’s Vista Bank acquires two BNP units

Private Equity4 hours ago

Secha Capital holds first close for $30mln impact fund

Private Equity4 hours ago

Gaia lists infrastructure fund on South Africa’s 4AX

Venture Capital5 hours ago

Societal shift away from cash sends Novatti transaction volumes soaring

Press Releases5 hours ago

BIG NEWS: Endangered White Rhino Born at Disney’s Animal Kingdom Theme Park

Private Equity7 hours ago

No title

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Press Releases7 hours ago

MÉXICOPUEDE.MX, en alianza con Cisco México, brinda asesoría a PYMES

Venture Capital8 hours ago

Robo-advice a complement, not disruptor: Six Park

Venture Capital8 hours ago

TrueLayer heads down under as it begins global expansion

Press Releases8 hours ago

Dunkin’ Brands Group, Inc. Statement about Possible Acquisition

Venture Capital8 hours ago

‘No hard and fast rule’: Fintechs and banks size each other up

Press Releases9 hours ago

SAP SE: Strong Double-Digit Growth in EPS and Cash Flow

Private Equity10 hours ago

MCC and Africa50 plan infra investment platform launch

Saas10 hours ago

Saas10 hours ago

Saas10 hours ago

Saas10 hours ago

Trending